Click here to read the Cover Story, "Experts weigh current, future options for AMD management."
Longer-acting drugs have been a great addition to our armamentarium.
However, from the studies and our own experience, we have learned that they are not 100% effective in all patients and that with the longer intervals in between injections of 16, 20 or 24 weeks, some patients may have attrition at certain periods of time. And certainly, not 100% of patients are able to achieve the full interval of re-treatment. The clinical trials did intermediate monitoring in those patients, and I believe this is